A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Verastem, Inc.
Study ID
NCT07644559
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • G12D Mutated KRAS
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • VS-7375 — DRUG
    Taken by mouth
  • cetuximab — DRUG
    Subcutaneous infusion

Study Details

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Key Dates

First listed
Jun 12, 2026
Start date
Jun 16, 2026
Status verified
Jul 2026
Primary completion
Jun 30, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: VS-7375 Monotherapy
  • Experimental: VS-7375 + cetuximab 2L PDAC
  • Experimental: VS-7375 + cetuximab 1L PDAC

Primary Outcome Measure

Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 [ Time Frame: 6 months ]

Central Contacts

Locations (18)

FacilityCityStateZIPSite coordinators
START- Los AngelesLos AngelesCalifornia90025
Navid Hafez, MD (PRINCIPAL_INVESTIGATOR)
Valkyrie Clinical TrialsLos AngelesCalifornia90067
Trenis Palmer
[email protected]
4245351874
David Berz, MD (PRINCIPAL_INVESTIGATOR)
Moffitt Cancer CenterTampaFlorida33612
Brianna Holder
[email protected]
Dae-Won Kim, MD (PRINCIPAL_INVESTIGATOR)
Johns Hopkins UniversityBaltimoreMaryland21287
Colleen Apostol
[email protected]
Mari Nakazawa, MD (PRINCIPAL_INVESTIGATOR)
Dana-Farber Cancer InstituteBostonMassachusetts02215
Danielle Lindquist
[email protected]
857-215-2351
Kimberly Perez, MD (PRINCIPAL_INVESTIGATOR)
START MidwestGrand RapidsMichigan49546
Sreenivasa Chandana, MD (PRINCIPAL_INVESTIGATOR)
Washington UniversitySt LouisMissouri63110
Olive Pressey
[email protected]
Kian-Huat Lim, MD (PRINCIPAL_INVESTIGATOR)
START New JerseyEast BrunswickNew Jersey08816
Bruno Fang, MD (PRINCIPAL_INVESTIGATOR)
NYU-ManhattanNew YorkNew York10016
Monica Dureja
[email protected]
2122634415
Kristen Spencer, MD (PRINCIPAL_INVESTIGATOR)
University of North CarolinaChapel HillNorth Carolina27599
Catherine Griffin
[email protected]
Ashwin Somasundaram, MD (PRINCIPAL_INVESTIGATOR)
Sarah Cannon Research InstituteNashvilleTennessee37203
Karlie Williams
[email protected]
6153297274
Meredith Pelster, MD (PRINCIPAL_INVESTIGATOR)
START DallasFort WorthTexas76104
Salwan Almutar, MD (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77054
Michelle Escano-Caballero
[email protected]
7137941776
Shubham Pant, MD (PRINCIPAL_INVESTIGATOR)
START- San AntonioSan AntonioTexas78229
Drew Rasco, MD (PRINCIPAL_INVESTIGATOR)
START- Mountain RegionWest Valley CityUtah84119
Julianna Daley
[email protected]
William McKean, MD (PRINCIPAL_INVESTIGATOR)
UVA HealthCharlottesvilleVirginia22903
Clinical Trials Navigator
[email protected]
4349820539
Matthew Reilley, MD (PRINCIPAL_INVESTIGATOR)
Virginia Cancer SpecialistsFairfaxVirginia22031
Michelle Blair
[email protected]
4342437264
Alexander Spira, MD (PRINCIPAL_INVESTIGATOR)
UW HealthMadisonWisconsin53792
Cancer Connect
[email protected]
8006228922
Noelle LoConte, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
START- Los Angeles· Los Angeles, CAValkyrie Clinical Trials· Los Angeles, CAMoffitt Cancer Center· Tampa, FLJohns Hopkins University· Baltimore, MDDana-Farber Cancer Institute· Boston, MASTART Midwest· Grand Rapids, MI

Related Studies